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TheNational Advisory Committee on Immunization (NACI) providesmedical, scientiﬁc, and public health
advice on the use of vaccines in Canada. This article describes the structure and processes of NACI, as wellvidence-based recommendations
anada
as its approach to evidence-based decision-making. In a rapidly evolving and complex immunization
environment, NACI has faced challenges in its endeavour to make thorough and timely evidence-based
recommendations. Making population-level recommendations without formally considering the full
spectrum of public health science (e.g. cost-effectiveness) presents difﬁculties in the implementation of
NACI’s recommendations. Although an improved and more transparent evidence-based NACI decision-
making process is now in place, this is continuing to evolve with a current review of structures and
rther
n Copprocesses underway to fu
Crow
. Introduction
The scientiﬁc body in Canada that addresses one of the World
ealth Organization’s (WHO’s) priorities for “national immuniza-
ion technical advisory committees. . .as part of the process of
nsuring evidence-based decision-making at the country level” is
he National Advisory Committee on Immunization (NACI) [1].
As a federal state, responsibility for health in Canada is shared
y the national and provincial-territorial governments. Numerous
ederal–provincial–territorial consultative processes enable coor-
ination and collaboration among different levels of government
hile preserving local independence. The Public Health Agency of
anada (PHAC), created in 2004 and led by Canada’s Chief Public
ealth Ofﬁcer, is the main federal agency responsible for public
ealth. PHAC reports to Parliament through the Minister of Health,
nd collaborates closely with all levels of government (provincial,
Abbreviations: ACIP, United States Advisory Committee on Immunization Prac-
ices; CDC, United States Centers for Disease Control and Prevention; NACI, National
dvisory Committee on Immunization; PHAC, Public Health Agency of Canada;
HO, World Health Organization.
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territorial, municipal), as well as non-governmental organizations,
other countries, and international organizations like the WHO.
NACI is an expert advisory committee of the PHAC and was estab-
lished and mandated by the agency itself through its legislative
ability to seek views about public health issues [2].
NACI is charged with providing medical and scientiﬁc advice
on immunization for Canadians, focusing on scientiﬁc evidence to
evaluate vaccine safety and efﬁcacy. The planning and delivery of
immunization programs in Canada falls under the jurisdiction of
each province/territory. A federal/provincial/territorial committee,
the Canadian Immunization Committee, considers these program-
matic issues, including economic considerations, in light of NACI
statements, and produces recommendations to the Pan-Canadian
Public Health Network. The overarching framework for the admin-
istration of these committees is the National Immunization
Strategy (available at: http://www.phac-aspc.gc.ca/publicat/nis-
sni-03/index-eng.php). Recommendations for the prevention of
vaccine-preventable infections and other health hazards for Cana-
dians who travel outside Canada’s borders are made by a separate
scientiﬁc committee, theCommittee toAdviseonTropicalMedicine
Open access under CC BY-NC-ND license.and Travel.
A broad range of stakeholders depend on NACI’s recommen-
dations, including decision-makers in provinces and territories,
public health practitioners, health care providers, individuals; as
well as vaccine manufacturers, non-governmental organizations
-ND license.
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Table 1
List of Liaison Groups and ex ofﬁcio representation onNational Advisory Committee
on Immunization (NACI).
Liaison Groups Ex ofﬁcio representation
Association of Medical Microbiology
and Infectious Disease Canada
Biologic & Genetic Therapies
Directorate, Health Canada
Canadian Nursing Coalition for
Immunization
Canadian Forces Health
Services Group, Department of
National Defence
Canadian Pediatric Society Canadian Immunization
Committee, Immunization
Programs Division, Public
Health Agency of Canada
Canadian Public Health Association First Nations & Inuit Health
Branch, Health Canada
Centres for Disease Control Surveillance and Outbreak
Response, Public Health
Agency of Canada
College of Family Physicians of Canada Vaccine Safety, Public Health
Agency of Canada
Community Hospital Infection Control
Association
Committee to Advise on Tropical
Medicine and TravelS.J. Ismail et al. / Vac
e.g. professional societies and immunization advocacy groups),
nd federal departments (e.g. First Nations Inuit Health Branch,
itizenship & Immigration Canada, Department of National
efence). In fact, in a recent report from the national Advisor on
ealthy Children and Youth, it was recommended that “the federal
overnment continue to support thework of the National Advisory
Committee) on Immunization in getting valuable information to
ealth care providers and parents” [3].
. Description and background
In 1964, a committee called “The National Advisory Commit-
ee on Immunizing Agents” was established in Canada to facilitate
oordination with the provinces, and served as the principal advi-
ory agency to the Minister of National Health and Welfare. The
ommittee’s name was formally changed to the National Advisory
ommittee on Immunization (NACI) in June 1978. Since Octo-
er 2004, NACI has reported to the Chief Public Health Ofﬁcer of
anada who heads the Public Health Agency of Canada. The cur-
ent mandate of NACI is “to provide the Public Health Agency of
anada with ongoing and timely medical, scientiﬁc, and public
ealth advice relating to vaccines and certain prophylaxis agents
e.g., immunoglobulins)”.
NACI publishes its recommendations in an open-access
lectronic periodical called the Canada Communicable Dis-
ase Report (CCDR) (http://www.phac-aspc.gc.ca/publicat/ccdr-
mtc/index-eng.php), which is indexed in the MEDLINE of the
ational Library of Medicine, and Advisory Committee Statements
lso appear on the public website of NACI. With the support of
he Centre for Immunization and Respiratory Infectious Diseases
t PHAC, NACI publishes a handbook on vaccine and immuniza-
ion information called the Canadian Immunization Guide every
our years in hardcopy and pdf format. In the future, the Guide
ill be published in an evergreen, evolving electronic format. The
uide is seen as a useful and reliable resource by immunization
roviders across the country and is available at: http://www.phac-
spc.gc.ca/naci-ccni/index-eng.php.
Membership on NACI consists of twelve voting members from
crossCanadawhoare recognizedexperts in theﬁelds of pediatrics,
nfectious diseases, immunology, medical microbiology, internal
edicine, nursing, pharmacy and public health. There are eleven
iaison members from various organizations with interests in
mmunization, as well as six ex ofﬁcio members from relevant
reas within the federal government who contribute to working
roups and full committee discussions (Table 1). While liaison and
x ofﬁcio members do not vote on NACI recommendations, they
re integral to NACI’s work, and bring essential knowledge and
erspectives to the recommendation process.
Selection of NACI members is based on expertise in relevant
elds. Members are expected to express their personal opinions
s informed by their professional expertise, rather than, for exam-
le, the province or region they live in. Appointments are by the
hief Public Health Ofﬁcer, and reﬂect the PHAC’s policy that com-
ittee membership be fairly balanced in terms of points of view
epresented, diverse geographic areas and the committee’s func-
ion. Members are appointed for a term of four years and may be
equested to renew their membership for a second term of four
ears. Membership is reviewed on a regular basis by the Chair and
xecutive Secretary. When vacancies occur, calls for members are
ade public through the NACI website and to professional groups
e.g. liaison groups). Interested individuals are encouraged to sub-
it their curriculum vitae through the website.
The Chair of NACI is also appointed by the Chief Public Health
fﬁcer for a four-year termand is a non-votingmember of theCom-
ittee (unless there is a tie vote). Selection of the Chair is based
n expertise and knowledge in the ﬁeld of immunization prac-Council of Chief Medical Ofﬁcers of
Health
Society of Obstetricians and
Gynaecologists of Canada
tices, public health, and use of vaccines and prophylaxis agents
for the prevention of vaccine-preventable diseases. A Vice-Chair
selected from existing membership is also appointed for a four-
year term. The Vice-Chair becomes theNACI Chairwhen the Chair’s
term is complete. The Director of the Immunization and Respira-
tory Infectious Disease Division designates an Executive Secretary
who provides leadership and strategic advice for the Committee
and works closely with the Chair and the NACI Secretariat (cur-
rently comprised of two projectmanagers/assistants and one nurse
epidemiologist). Secretariat functions to NACI are provided for or
funded by the federal public health agency.
Liaison members of NACI are representatives from groups iden-
tiﬁed by the Chief Public Health Ofﬁcer to provide expertise on
vaccine safety and effectiveness, and/or provide input to ensure
appropriate interpretation of NACI’s advice, and/or have access to
relevant research on speciﬁc issues. Liaison members are selected
by their organizations, and are expected to bring knowledge and
input into the NACI discussions, express the views of the orga-
nization, and communicate NACI’s advice to the organization as
permitted.
Ex ofﬁcio representatives on NACI are assigned by the Director
General of the Centre for Immunization & Respiratory Infectious
Diseases of the Public Health Agency of Canada. The role of the ex
ofﬁcio members is to support the work of NACI and the agency
by providing additional knowledge and expertise, communicating
the views of the Department/Agency/Division they represent (e.g.
First Nations and Inuit Health Branch), and communicating NACI’s
advice as permitted by the PHAC.
Vaccine industry representatives cannot be members of NACI,
and do not participate in group discussions. Industry experts do
provide information about vaccines to the Committee, and may be
invited to make presentations to the full committee or its working
groups. NACI is not funded in any way by the vaccine industry.NACI Working Groups are established to address speciﬁc vac-
cine and immunization issues. These groups review evidence and
draft Advisory Committee Statements on speciﬁc vaccines, includ-
ing options for vaccine recommendations for the full committee
to consider. Working groups may prepare guidance in response to
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level of evidence based on research design (e.g. Level I for evidence
fromrandomized controlled trials) andanassessmentof thequality
(internal validity) of the study is made (i.e. Good, Fair, Poor-based
on design-speciﬁc criteria as outlined in Harris et al., 2001 [4]). The
full knowledge synthesis includes a review of the product mono-
Table 2
National Advisory Committee on Immunization (NACI) recommendation for
immunization—grades.
A NACI concludes that there is good evidence to recommend
immunization.
B NACI concludes that there is fair evidence to recommend
immunization.
C NACI concludes that the existing evidence is conﬂicting and does
not allow making a recommendation for or against immunization,
however other factors may inﬂuence decision-making.
D NACI concludes that there is fair evidence to recommend against
immunization.60 S.J. Ismail et al. / Vac
peciﬁc inquiries or other issues as they arise, and are also asked to
ontribute to and revise relevant chapters of the Canadian Immu-
ization Guide.Working Groups are comprised of voting and liaison
embers, PHAC staff and external experts as necessary.
Working group chairs are members of NACI or others who
re appointed as deemed appropriate by the Committee Chair.
embers (including votingmembers, liaisonmembers, and ex ofﬁ-
io members) are asked to volunteer to participate in working
roups based on their expertise and interest.Working groupsmust
nclude one or more regular voting members as well as one medi-
al specialist from the PHAC (as Medical Lead). There are currently
wo Medical Leads (including the Executive Secretary) distributed
mong eighteen working groups. A PHAC Medical Lead is a physi-
ian who works closely with the Working Group chair and NACI
ecretariat to assist with the technical analysis, literature review,
nddrafting of AdvisoryCommittee Statements in addition to other
oles and responsibilities, such as responding to medical inquiries
o NACI. External content experts or other consultants may be
nvited to serve on a Working Group (e.g. representatives from the
anadian Immunization Committee or the Committee to Advise on
ropical Medicine and Travel) as necessary to provide broad input.
. Terms of reference, meeting processes, and declaration
f conﬂicts of interest
.1. Terms of reference
Information on NACI’s structure and processes is contained
ithin its Terms of Reference, available publicly on the PHAC
ebsite (http://www.phac-aspc.gc.ca/naci-ccni/tor-eng.php#12).
hese Terms of Reference may be amended at any meeting by
onsensus or by vote.
.2. Meeting processes
The National Advisory Committee on Immunization has three
ace-to-face meetings a year which occur over 2 days. Ad hoc tele-
onferences of the full committee are held as needed, and email
orrespondenceoccurs regularly.Meetings arenot open to thepub-
ic. Additional observers (e.g. health care students/post-graduate
hysician trainees or PHAC staff) may attend upon request and
pproval of the NACI Executive Committee, and after agreeing
o conﬁdentiality requirements. Experts, including representatives
rom vaccinemanufacturers, may be invited tomake presentations
s needed.
For each meeting, detailed Minutes and a succinct Summary of
iscussions are prepared by the Secretariat, reviewed by the Exec-
tive Secretary and Chair of NACI, and approved by the NACI. The
ummaryofDiscussions is used for information sharingbeyondNACI
owever the detailedMinutes is a conﬁdential document that is not
istributed beyond the Committee.
The agenda for NACI meetings is created based on changes in
he epidemiology of vaccine-preventable diseases, new products,
r new evidence about existing products. Potential topics may be
ubmitted by committeemembers and other stakeholders, and are
ccepted for addition to the agenda by the Executive Secretary, in
onsultation with the Chair. An executive committee (consisting
f the Chair, Vice-Chair, Executive Secretary, PHAC Medical Leads
nd NACI Secretariat) meets regularly by teleconference between
eetings to oversee the progress of the Working Groups, plan full
ACI meetings and deal with inter-current issues that arise..3. Declaration of conﬂicts of interest
Members, liaison representatives and consultants are required
o submit annual conﬂict of interest declarations to the Executive8S (2010) A58–A63
Secretary, basedonConﬂict of InterestGuidelines. Anycircumstances
thatmayplace, or be seen to place themember in a real, apparent or
potential conﬂict of interest should be disclosed on a written form.
It is incumbent upon the member to update this disclosure should
his/her personal situation change. Members, representatives and
consultants are expected to conduct themselves in an appropriate
manner and in accordance with the NACI guidelines.
In situations where a conﬂict of interests or the appearance
thereof arises in the course of the work of the committee, the indi-
vidual involved must declare its existence and either work with
the Executive Secretary to resolve the conﬂict, or if necessary, dis-
qualify himself/herself from participation in the discussion or from
further participation on the committee according to the circum-
stances of speciﬁc situations.
4. Development of recommendations and the basis for
decision-making
In January 2009, NACI formally introduced its process to
develop and grade evidence-based recommendations through
the publication of its Statement: “Evidence-based recommen-
dations for immunization—Methods of the National Advisory
Committee on Immunization” (available at: http://www.phac-
aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-1/index-eng.php).
Publication of this process is intended to provide a transparent and
clear description of the methods used for retrieving, synthesizing
and weighing evidence that leads to a NACI recommendation.
In brief, the stages for the development of NACI recommenda-
tions are:
1. Knowledge synthesis (retrieval and summary of individual stud-
ies on vaccine safety, efﬁcacy, immunogenicity, effectiveness,
ranking of the level and quality of evidence of each study).
2. Synthesis of the body of evidence of beneﬁts and harms, con-
sidering the relevance, quality of the evidence andmagnitude of
effects observed.
3. Translation of summarized evidence into recommendations
associated with a qualitative recommendation grade (Table 2).
The relevantNACIWorkingGroup is responsible for establishing
the scope of and requirements for the literature review. The litera-
ture reviewmay be contracted out to an external group/consultant,
or performed within the PHAC. As part of the literature review,
evidence tables are assembled in which each study is assigned aE NACI concludes that there is good evidence to recommend against
immunization.
I NACI concludes that there is insufﬁcient evidence (in either
quantity and/or quality) to make a recommendation, however
other factors may inﬂuence decision-making.
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raph, scientiﬁc literature on the burden of disease (epidemiology,
orbidity, mortality) in the population in general and in speciﬁc
isk groups, vaccine characteristics (e.g. safety, immunogenicity,
fﬁcacy, effectiveness), in addition to various scientiﬁc factors out-
ined in “An Analytic Framework for Immunization Programs in
anada” [5]. Recommendations fromother groups (e.g.WHO, Advi-
ory Committee on Immunization Practices, Canadian Pediatric
ociety) are reviewed. The Working Group prepares recommen-
ation options for consideration by the full NACI committee. The
edical Lead and the NACI Working Group Chair review all indi-
idual studies, but all the assembled evidence is available to the
orking Group and to NACI.
Following full committee review and discussion of the
ata, draft Advisory Committee Statement, and recommendation
ptions prepared by the Working Group, the NACI votes. Voting
s restricted to the twelve members of NACI and occurs through
n open process. A quorum of at least two thirds of members is
equired to authenticate a vote. Members who have been absent
or all discussions and not able to review all background documen-
ation are not permitted to vote in advance of meetings or calls.
The ﬁnal NACI Advisory Committee Statement, incorporating
ommittee discussion and vote, is circulated by email for approval.
fter this approval and ﬁnal review by the NACI Chair and Exec-
tive Secretary, the document is sent to the Chief Public Health
fﬁcer for ﬁnal approval. Once edited and translated into both
fﬁcial languages in Canada (French and English), approved NACI
tatements are usually published in the Canada Communicable Dis-
ase Report (http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/) and
ccasionally reprinted in other publications. They are also available
n the PHAC website (http://www.phac-aspc.gc.ca/naci-ccni/recs-
ng.php), along with the separately posted literature review that
upported the development of the Advisory Committee Statement
nd the recommendations.
Recently NACI agreed to use a common template for Advi-
ory Committee Statements. This includes: (1) an introduction
overview of previous NACI recommendations, national goals for
he vaccine-preventable disease/immunization coverage, new evi-
ence triggering the need for a new statement, methodology of the
vidence-based review); (2) summary of the disease epidemiology;
3) summary of the vaccine characteristics; (4) recommendations
nd rationale; (5) research priorities; and (6) surveillance gaps.
. Consideration of various scientiﬁc (e.g. vaccine efﬁcacy)
nd programmatic (e.g. cost) factors for decision-making
As noted, national immunization recommendations are devel-
ped using an “Analytic Framework for Immunization Recom-
endations in Canada” [5]. This framework outlines a number of
cientiﬁc (e.g. disease burden, vaccine characteristics) and pro-
rammatic (e.g. feasibility, acceptability, ethics, cost) factors that
hould be considered when making decisions regarding immu-
ization programs. NACI considers the scientiﬁc factors within this
ramework, and the Canadian Immunization Committee builds on
ACI’s work to additionally consider the factors inherent in pro-
ram planning and delivery that are outlined in the framework.
One challenge that NACI has faced is that it does not explicitly
onsider economic aspects of vaccine use since this responsibil-
ty has been delegated to the Canadian Immunization Committee.
wareness of the cost of vaccines and vaccine programs may be
ifﬁcult to partition from discussions of the value of a vaccine to
ndividual Canadians or broader populations. NACI may recom-
end that such factors be considered by local decision-makers
r individual healthcare providers when applying NACI guidance.
he following excerpt from the recent “Update on the Invasive
eningococcal Disease (IMD) and Meningococcal Vaccine Conju-
ate Recommendations” illustrates this [6]:8S (2010) A58–A63 A61
Choice of products for early adolescent dose:
“The early adolescent dose could be given using either
meningococcal C conjugate vaccine or quadrivalent conjugate
meningococcal vaccine. Provinces/territories will need to con-
sider their burden of illness from serogroups A, Y and W135
and the age distribution of cases by serogroup which provide
an indication of the number of IMD cases that might be pre-
vented. They will also need to consider the differential in cost
betweenmonovalent and quadrivalent products and other local
factors.”
<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/acs-
dcc-3/index-eng.php>
6. Role of the committee in the ultimate decision-making
process
NACI recommendations are used by provinces, territories,
professional associations, advocacy groups and individual care
providers. Since health care delivery in Canada is a provin-
cial/territorial responsibility, variation inapplicationof recommen-
dations does occur. For the most part, jurisdictions adhere to NACI
recommendations but the timing and logistics of program imple-
mentation may vary due to differences in local existing programs,
resources and epidemiology. Jurisdictions also may consider the
Canadian Immunization Committee’s recommendations regarding
programdelivery options before planning local programs. Vaccines
deliveredby individual careprovidersoutsideof governmentalpro-
grams could be paid for by the patient, by their employer or by
individual or group health insurance plans.
Variability in the implementation of NACI recommendations,
for example, is apparent in provincial schedules for meningococcal
vaccine across the country, and the timing of program implementa-
tion. Since 2001, NACI has recommended the use of meningococcal
C conjugate vaccine for infants, children from 1 to 4 years of age,
adolescents and young adults [7]. While some provinces began
implementing routinemeningococcal C conjugate vaccination pro-
grams in 2002, it was not until 2007 that every province had a
routine program.
NACI recommendations are seen in many cases as setting a
standard of care or “best practice”. According to the CanadianMed-
ical Protection Association – the organization through which most
physicians hold malpractice insurance – a physician is obliged to
inform a patient of new vaccine recommendations made by agen-
cies such as NACI. They note that patients must be made aware of
“any ofﬁcial recommendations from authoritative groups, such as
governments and medical specialty associations” as well as “any
cost of the vaccine if it is not covered by the provincial/territorial
health plan. Physician concerns regarding cost issues should not
preclude informing the patient/legal guardian about vaccination
options” [8].
7. Communication activities and training practices
7.1. Communication activities
NACI disseminates information related to its activities to health
professionals and the public via electronic mail distribution alerts
that a new Advisory Committee Statement has been posted on the
publicly available CCDR site, via the Canadian Immunization Guide
(http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php) and
on the main NACI website (http://www.phac-aspc.gc.ca/naci-
ccni/). NACI also responds to inquiries submitted by stakeholders
(including members of the public and health professionals) about
its recommendations and guidance.
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Communication between members, liaison and ex ofﬁcio rep-
esentatives and the NACI Secretariat occurs via email, telephone
onference and face-to-face meetings. NACI also communicates
ith its counterpart committee in the United States, the Advisory
ommittee on Immunization Practices (ACIP) of the Centers for
isease Control and Prevention (CDC). CDC has a standing liaison
ember on NACI and a representative of NACI is a liaison member
f ACIP.
.2. Training
The NACI Secretariat provides a new member orientation,
ncluding provision ofmaterials addressing administrativematters
e.g. conﬁdentiality guidelines), and key background documents on
he process and methodology of Working Groups and the recom-
endation development process. Documents on the role of liaison
nd voting member responsibilities are provided.
Learning objectives for each NACI meeting are outlined in
he agenda, and continuing professional development credits are
ssigned for educational components of the meeting. Experts in a
articular ﬁeld may be invited to present to NACI to inform mem-
ers on a particular topic of interest with relevance to themandate
f the Committee. Additional training topics may be suggested by
ommittee members and arrangements for information/training
essions are made by the Secretariat.
. Challenges, limitations and future developments
Like most immunization advisory committees, NACI has faced
hallenges in a rapidly evolving and complex immunization envi-
onment. Expectations of this committee have escalated with an
ncreasing number of vaccines for the same infectious agent (e.g.
ultivalent pneumococcal conjugate vaccines), increasing com-
lexity of vaccines (e.g. new adjuvants), increasing spectrum of
accine recipients (e.g. older females for HPV vaccine), increas-
ng spectrum of vaccine-preventable diseases (e.g. cervical cancer
s a chronic disease with a long incubation period), increasing
urveillance needs to consider the public health impact of vac-
ines (e.g. diseases that are not reportable), increasing complexity
f immunization schedules, and increasing demands from stake-
olders for improved information sharing and shorter timelines
rom vaccine regulatory approval to public statement release. Over
he years, a rising number of Advisory Committee Statements
ave been required (e.g. four published in 2004 compared to
ine in 2007). NACI’s commitment to a systematic, transparent
vidence-based process involves a great deal of effort, especially
ith the volume of evidence that is rapidly generated and pub-
ished. This involves a tremendous effort on the part of volunteer
embers, and new public health human resource capacity from
he PHAC. The Advisor on Healthy Children and Youth recognized
hese challenges and noted in her report that “NACI is a commit-
ee resourced by volunteers, and support for these individuals is
equired” [3].
NACI members have noted the challenge inmaking population-
evel recommendations without formally considering the full
pectrum of public health science (e.g. cost-effectiveness), espe-
ially in an era of increasingly expensive vaccines. While NACI and
he Canadian Immunization Committee have successfully collabo-
ated inmaking immunization recommendations, it has beennoted
hat streamlining the work of the committees to reduce duplica-
ion of efforts may lead to improved efﬁciency and effectiveness
f immunization recommendations. As such, a review to Improve
he National Structures and Processes for making Immunization
ecommendations (INSPIR) is in progress.8S (2010) A58–A63
9. Summary and conclusions
While NACI has faced challenges in effectively and efﬁciently
fulﬁlling its mandate in an increasingly complex immunization
environment, it has been successful in providing relatively timely
immunization recommendations to Canadians. NACI is a respected,
credible, scientiﬁc advisory committee of dedicated expert mem-
bers, as evidencedby comments on the value ofNACI by theAdvisor
on Healthy Children and Youth in her recent report [3], links to
NACI statements on various national organizations’ websites (e.g.
Canadian Pediatric Society), implementation of immunization pro-
grams across Canada following the publication of NACI’s Advisory
Committee Statements, and speciﬁc reference to NACI by the Cana-
dianMedical Protective Agency outlining physicians’ obligations to
inform their patients of vaccine recommendations.
As noted previously, there are several other committees in
Canada, not reviewed in detail here, that play roles in an overar-
ching Canadian National Immunization Strategy. Communication,
collaboration, and coordination between NACI and other stake-
holders is improving. The process and timeliness of release of
NACI statements is improving through the formalization of work-
ing group review process and support, and the development
of project plans. Support for continuing professional develop-
ment and recruitment of the next generation of vaccine experts
has become a priority, with the development of procedures for
post-graduate physician trainees and health care students to get
exposure to NACI as observers. Furthermore, face-to-face NACI
meetings are now accredited for continuing professional develop-
ment credits.
Support for evidence-based recommendations has improved
through formal literature reviews, and a transparent approach of
critical appraisal and ranking of evidence in NACI statements. In
recognition of rapidly evolving evidence and the need for up-to-
date recommendations for immunization providers, the Canadian
Immunization Guide is being transformed to aweb-based evergreen
format aligned with the NACI Statement development process
(rather than as a hardcopy manual published every four years).
Planning is underway to organize alerts to stakeholders as chap-
ters are updated, and to have the chapters of the Guide available to
download and print and be PDA-accessible. The evergreen, evolv-
ing, electronic Canadian Immunization Guide is intended to improve
the efﬁciency, timeliness, and access to up-to-date immunization
information that is consistent with the recommendations of new
NACI statements as they are published.
Canada’s national immunization technical advisory committee
has evolved since its establishment in1964, andcontinues to evolve
with the changing immunization environment. Through ongoing
collaboration with partners within and outside Canada, the NACI
endeavours to meet the WHO’s priority to “strengthen national
immunization technical advisory committees (NITAGs), increas-
ingly called for given the complexity of immunization programmes
and high cost of new vaccines” [1].
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